Quick Takeaways:
- ECO Animal Health announced that the USDA-CVB has accepted field safety data for Ecovaxxin MS, its poultry vaccine against Mycoplasma synoviae, confirming the data meets requirements supporting US licensure.
- The field safety trial involved more than 170,000 commercial laying pullets across three sites in Michigan, Indiana, and Wisconsin. The vaccine was commercially launched in the EU in July 2026.
- The milestone advances Ecovaxxin MS toward U.S. marketing authorization, which ECO expects by the end of 2026, while supporting the company’s broader geographic expansion and proprietary R&D pipeline.
Why It Matters?
ECO Animal Health’s acceptance of field safety data for Ecovaxxin MS by the USDA‑CVB is a key regulatory step toward US licensure of its Mycoplasma synoviae poultry vaccine, following the product’s EU commercial launch in July 2026. The large field trial (over 170,000 laying pullets across three US sites) de‑risks safety for US regulators and producers, positioning ECO to potentially capture share in the US layer market if authorization is granted by end‑2026, while reinforcing its strategy of rolling out proprietary vaccines first in Europe and then in North America.
Source: ECO Animal Health
